<DOC>
	<DOCNO>NCT02757950</DOCNO>
	<brief_summary>The purpose study assess safety RefortrixTM ( Tdap ) administer pregnancy maternal immunization program Brazil .</brief_summary>
	<brief_title>A Post-marketing , Observational , Retrospective Study Assess Safety RefortrixTM ( Tdap ) When Administered During Pregnancy Maternal Immunization Program Brazil .</brief_title>
	<detailed_description>In retrospective cohort study safety RefortrixTM ( Tdap ) administer pregnancy part National immunization program Brazil assess compare risk pre-defined adverse event introduction RefortrixTM ( Tdap ) maternal immunization program .</detailed_description>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects 18 45 year age time pregnancy consideration study , deliver study centre . Residents study area Subjects compliant routine antenatal care include least one ultrasound assessment report early pregnancy . Subjects complete relevant medical record available . Inclusion criterion Exposed cohort : Subjects receive one dose Refortrix vaccine recommend time period 27 36 complete week pregnancy ( late 20 day delivery due date ) part maternal immunization program Brazil , accord program recommendation May 2015 onwards . Subjects appropriate vaccination record . Inclusion criterion Unexposed cohort : Subjects deliver hospital ( study centre ) 01 September 2014 ( September 2012August 2014 ) receive Tdap vaccination pregnancy best knowledge investigator . Subjects transfer specialised centre , medical record would inaccessible study ( private clinic , psychiatric prison hospital , state hospital , etc ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>expose unexposed cohort</keyword>
	<keyword>post-marketing , maternal immunization</keyword>
	<keyword>neonate related Adverse Events</keyword>
	<keyword>Congenital anomaly</keyword>
	<keyword>RefortrixTM</keyword>
	<keyword>Pregnancy related Adverse Events</keyword>
</DOC>